Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/
Sai Life Sciences’ Veterinary APIs Unit in Bidar, India.
The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies.
Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said: “This investment strengthens our ability to meet the growing global demand for high-quality veterinary pharmaceuticals while ensuring the highest standards of innovation, efficiency, and sustainability. We are proud to support our innovator partners in their mission of offering reliable solutions that enhance animal well-being.”
The market for veterinary APIs presents a significant growth opportunity, driven by increasing demand for veterinary medicines and advancements in animal healthcare. Sai Life Sciences’ investment in this facility aligns with its strategic vision to enhance its offerings in niche, high-value segments of the pharmaceutical industry. With over two decades of manufacturing expertise, Sai Life Sciences has established itself as a trusted partner in API production, known for its advanced process capabilities, operational excellence, and stringent quality standards. The new facility leverages advanced technologies, robust supply chain management, and best-in-class safety practices to ensure reliable and cost-effective manufacturing of animal health APIs.
About Sai Life Sciences:
Sai Life Sciences is a leading integrated contract research, development, and manufacturing organisation (CRDMO). We work with over 300 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes. Over the past 26 years, we have served a diverse set of programmes, consistently delivering value based on our quality and responsiveness. We have over 3,400 employees across our facilities in India, UK and USA. https://www.sailife.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250918612071/en/
Contacts
For further information, contact:
Sriram Gopalakrishnan
Vice President, Corporate Communication
Sai Life Sciences Limited
Ph: +91 9121295355
sriram.g@sailife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release
Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release
AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by
illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release
illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont
Textron Aviation Broadens Aftermarket Connectivity Solutions for Cessna Citation Latitude by Offering Starlink High-Speed Internet18.9.2025 16:30:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an additional high-speed internet connectivity solution for the Cessna Citation Latitude following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. AeroMech’s STC utilizes Starlink’s constellation of Low Earth Orbit (LEO) satellites to provide more reliable connectivity over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918380069/en/ Textron Aviation broadens aftermarket connectivity solutions for Cessna Citation Latitude by offering Starlink high-speed internet (Photo Credit: Textron Aviation) “With Starlink connectivity now available as an upgrade, Citation Latitude customers can enjoy a seamless, high-speed in-flight experience that keeps them connected in more
Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 16:00:00 EEST | Press release
As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. Taking place on October 15, 2025, at the iconic Shangri-La at The Shard in London, Elevate'25 moves beyond the headlines to provide a practical roadmap for success, featuring insights from brand executives and industry-defining keynotes. "Unprecedented advancements in AI and mobile-first consumer behaviors are driving a seismic shift that is reshaping how brands interact with customers now and far into the future,” sa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom